



# Notice of Q1 FY22 Results

December 2, 2021

RNS Number : 2978U  
Renalytix PLC  
02 December 2021

**Renalytix plc**  
**("Renalytix" or the "Company")**

## **Renalytix to Report First Quarter Fiscal Year 2022 Financial Results on December 7**

**LONDON and SALT LAKE CITY, December 2, 2021** -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EST) / 1:30 p.m. (GMT).

### **Conference Call Details:**

US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551  
US/Canada Participant International Dial-In Number: (914) 987-7290  
United Kingdom International Dial-In Number: 0800 0288 438  
United Kingdom Local Dial-In Number: 0203 1070 289  
Conference ID:2495524

**Webcast Registration link:** <https://edge.media-server.com/mmc/p/2s8cwr7x>

***For further information, please contact:***

**Renalytix plc**  
James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)  
**Via Walbrook PR**

**Stifel (Nominated Adviser, Joint Broker)**  
Alex Price / Nicholas Moore

**Tel: 020 7710 7600**

**Investec Bank plc (Joint Broker)**  
Gary Clarence / Daniel Adams

**Tel: 020 7597 4000**

**Walbrook PR Limited**  
Paul McManus / Lianne Cawthorne

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)  
**Mob: 07980 541 893 / 07584 391 303**

**CapComm Partners**

Peter DeNardo

Tel: 415-389-6400 or [investors@renalytix.com](mailto:investors@renalytix.com)**About Renalytix**

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit [www.kidneyintelx.com](http://www.kidneyintelx.com)). For more information, visit [www.renalytix.com](http://www.renalytix.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORUPGBWPUPGPUG